**Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in *Mycobacterium tuberculosis***

Diana Machado¹, Isabel Couto¹,², João Perdigão³, Liliana Rodrigues¹, Isabel Portugal³, Pedro Baptista⁴, Bruno Veigas⁴, Leonard Amaral¹,⁵, Miguel Viveiros¹,⁵

¹Grupo de Micobactérias, Unidade de Microbiologia Médica, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa (IHMT/UNL), Lisboa, Portugal, ²Centro de Recursos Microbiológicos (CREM), Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal, ³Centro de Patogénese Molecular/URIA, Faculdade de Farmácia, Universidade Nova de Lisboa, Lisboa, Portugal, ⁴CIGMH, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal, ⁵COST ACTION BM0701 (ATENS), Bruxells, Belgium

**Abstract**

Multidrug resistant (MDR) tuberculosis is caused by *Mycobacterium tuberculosis* resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy. Here, we investigated the mechanism by which resistance towards isoniazid develops and how overexpression of efflux pumps favors accumulation of mutations in isoniazid targets, thus establishing a MDR phenotype. The study was based on the *in vitro* induction of an isoniazid resistant phenotype by prolonged serial exposure of *M. tuberculosis* strains to the critical concentration of isoniazid employed for determination of drug susceptibility testing in clinical isolates. Results show that susceptible and rifampicin monoresistant strains exposed to this concentration become resistant to isoniazid after three weeks; and that resistance observed for the majority of these strains could be reduced by means of efflux pumps inhibitors. RT-qPCR assessment of efflux pump genes expression showed overexpression of all tested genes. Enhanced real-time efflux of ethidium bromide, a common efflux pump substrate, was also observed, showing a clear relation between overexpression of the genes and increased efflux pump function. Further exposure to isoniazid resulted in the selection and stabilization of spontaneous mutations and deletions in the katG gene along with sustained increased efflux activity. Together, results demonstrate the relevance of efflux pumps as one of the factors of isoniazid resistance in *M. tuberculosis*. These results support the hypothesis that activity of efflux pumps allows the maintenance of an isoniazid resistant population in a sub-optimally treated patient from which isoniazid genetically resistant mutants emerge. Therefore, the use of inhibitors of efflux should be considered in the development of new therapeutic strategies for preventing the emergence of MDR-TB during treatment.

_Citation:_ Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, et al. (2012) Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in *Mycobacterium tuberculosis*. PLoS ONE 7(4): e34538. doi:10.1371/journal.pone.0034538

_Editor:_ Igor Mokrousov, St. Petersburg Pasteur Institute, Russian Federation

**Received** December 21, 2011; **Accepted** March 1, 2012; **Published** April 6, 2012

**Copyright:** © 2012 Machado et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by grant EU-FSE/FEDER-PDTC/BLA-MIC/71280/2006 and EU-QREN/COMPETE-PDTC/SAU-FCF/102807/2008 from Fundação para a Ciência e a Tecnologia (FCT), Portugal and Project “Early Molecular Detection of M/XDRTB in the Great Lisbon Healthcare Region”, Refa SDH49, from Fundação Calouste Gulbenkian (FCG), Portugal. Authors DM and LR were supported by grants SFRH/BD/65060/2009 and SFRH/BD/24931/2005 from FCT of Portugal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: mviveiros@ihmt.unl.pt

**Introduction**

Tuberculosis (TB) remains a serious public health threat around the world, and according to the World Health Organization, nearly two billion people are infected with *Mycobacterium tuberculosis*, with about 8.9 million of new TB cases and 1.3 million deaths in 2010 [1]. Moreover, multidrug resistant tuberculosis (MDR-TB), caused by *M. tuberculosis* simultaneously resistant to isoniazid and rifampicin, the two most effective anti-bacillary drugs used in TB therapy, represents a challenge to the control of the disease since 650,000 of the TB cases in 2010 are estimated to be MDR-TB cases [1].

Chromosomal gene mutation has been considered the single cause for antibiotic resistance in *M. tuberculosis*, with multidrug resistance arising as a consequence of sequential accumulation of spontaneous mutations in target genes [2]. Resistance to rifampicin is almost always due to point mutations in the rpoB gene encoding the β subunit of the RNA polymerase [3]. Furthermore, monoresistance to rifampicin is rare and almost all *M. tuberculosis* strains resistant to rifampicin are also resistant to isoniazid [2,4,5]. Isoniazid is a prodrug that requires activation by the catalase-peroxidase enzyme (KatG) [6] and its molecular target is InhA, a NADH-dependent enoyl acyl carrier protein reductase involved in the synthesis of mycolic acids [7]. The main mechanism of resistance to isoniazid is the occurrence of mutations in its activator, KatG [6,8], whereas mutations in the inhA gene represent the second most common mechanism. Together, mutations in these two genes are responsible for approximately 75% of the cases of *M. tuberculosis* resistance to isoniazid in the clinical setting [9]. Resistance to isoniazid has also been associated with mutations in several other genes (*e.g.* mth, kasA and oxyR-ahpC intergenic region) [10], but its direct association with resistance is still unclear.

Isoniazid is highly effective against *M. tuberculosis* (bactericidal at low concentrations), the reason why it remains a key component in multiple drug treatment regimens. However, resistant isolates are rapidly generated during monotherapy or inappropriate treatment, and many clinical isolates with no identified mutation have
been described [9,11]. As with other bacterial species, these resistant phenotypes also receive significant contributions from membrane transport proteins that prevent the compound from reaching the cellular target [12,13]. The analysis of genome sequences has shown that mycobacteria have multiple putative efflux pumps [14] and to date, several pumps have been identified in various species of mycobacteria in association with low level resistance to various compounds, including isoniazid [15–20].

In general, increased activity of efflux systems is responsible for conferring low-level resistance to antibiotics, contrasting with the high-level resistance caused by mutations in genes encoding for the primary targets of these antibiotics [21]. Increased activity of efflux systems results in the reduction of intracellular levels of the antibiotic, which may enable the survival of a bacterial subpopulation under constant stress promoted by a sub-lethal level of antibiotic. During this period, mutants with alterations in the genes that favour resistance can be selected, therefore insuring the establishment of an antibiotic resistant population that is clinically significant [22–24]. It is this sub-population of bacteria that may then accumulate mutations with prolonged exposure to a constant concentration of antibiotic [25,26].

Here, we investigated the mechanisms underlying the development of multidrug resistance in M. tuberculosis via the constant exposure of several isoniazid susceptible M. tuberculosis strains to the critical concentration of isoniazid, 0.1 µg/ml; followed by the evaluation of the effect of efflux inhibitors on the isoniazid minimum inhibitory concentration for the original and isoniazid exposed resistant strains. Analysis of gene expression of six efflux pumps related to isoniazid resistance in M. tuberculosis [12,15,19] and its correlation with the cell's ability to efflux ethidium bromide (a common efflux substrate), provides strong evidence that when challenged with isoniazid, M. tuberculosis reacts by a prompt efflux-mediated response. We further demonstrate that this isoniazid induced resistance can be reverted by efflux inhibitors, supporting their role as adjuvants in anti-tuberculosis therapy and prevention of MDR-TB emergence.

Results

Exposure to isoniazid

Two M. tuberculosis strains susceptible to the first-line antibiotics (including the H37Rv reference strain) and two clinical strains monoresistant to rifampicin were constantly exposed to the critical concentration of isoniazid, 0.1 µg/ml, during an extended period of time – see Figure 1. Two independent exposure processes were carried out for each strain (exposure process A and B in Figure 1) to assess the stochastic behaviour of the biological events involved. The effect of 0.1 µg/ml isoniazid exposure on the minimum inhibitory concentration of isoniazid (INH MIC) is summarised in Table 1. Briefly, INH MIC increases from an initial value of 0.05–0.1 µg/ml to as high as 256 µg/ml (Table 1). Exposure to isoniazid had no effect on the MIC of rifampicin against all strains (data not shown). Additionally, susceptibility testing for the five 1st line antibiotics (streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide) applied to all strains at the beginning of the experiments and after the last passage in isoniazid indicated that development of resistance was restricted to isoniazid only (data not shown). We also observed that the time required for growth detection decreased with the number of passages (Table 1).

Typing by MIRU-VNTR analysis

To confirm the isogenic nature of the exposed and initial parental strains, all strains were subjected to molecular typing by MIRU-VNTR analysis, which confirmed the identity of each culture during the antibiotic exposure processes (Tables 2 and 3).

Detection of mutations associated with isoniazid resistance

Cultures corresponding to selected passages of isoniazid exposure were preliminarily monitored for mutations in katG and mnhA-inkA operon by the Genotype MTBDRplus system. These strains were later analyzed by DNA sequencing of specific fragments of these same genes – see Tables 2 and 3.

For strain H37Rv, two different results were obtained for the two independent isoniazid exposure processes. In one of the duplicates, total deletion of katG gene was observed at passage #3 (H37RvINH#03. GenBank accession number JQ406385). The precise extent and location of this deletion was defined by sequencing and chromosomal primer walking to be located between positions 5′-2150314 and 5′-2159943 of the M. tuberculosis H37Rv genome [14]. This deletion, 8084 bp in length, resulted in the complete loss of genes Rs9003, Rs9004, anu, Rs9010e, Rs907e, katG, furA, Rs910c, lppc and disruption of fabB5 (Figure 2). Conversely, no alterations were detected on katG or any of the other gene targets tested during strain H37Rv second isoniazid exposure process (cf. Tables 2 and 3). Interestingly, both isoniazid-exposed cultures evidenced the same levels of resistance at equivalent passages of the exposure process (Table 1). For the three clinical strains subjected to the same isoniazid exposure process, no alterations were detected, except for the appearance of a STOP codon in position 1314 of the katG gene (codon 438) for strain 359/03 This alteration occurred at passage #2 (359/03INH#02; accession number JQ316462) of the first exposure process (Table 2), whereas no alteration was detected in the second exposure process of the same strain (Table 3). Again, no differences were observed between the isoniazid resistance levels of the two isoniazid-exposed cultures 359/03 (Table 1).

Effect of EIs on the susceptibility to isoniazid

To test for the involvement of efflux on the increased resistance to isoniazid noticed through the exposure process, we determined the INH MIC in the first passage where this increased resistance was first noticed and in last passage (359/03) of the exposure process, in the absence and presence of compounds known to act as efflux inhibitors (EIs). The compounds selected were thioridazine, chlorpromazine and verapamil, for which inhibitory activity against mycobacterial efflux pumps was already demonstrated [16,27,28]. The effects of these EIs on the INH MICs are summarized in Table 4. The INH MIC was reduced by thioridazine, chlorpromazine and verapamil to levels equal or below the critical concentration used for the standard susceptibility testing of this antibiotic in the majority of cases. We then assayed the efflux activity of these cultures by a semi-automated fluorometric method [27,29], which uses the broad-range efflux substrate EtBr, in the presence and absence of an EI.

Real-time detection of efflux activity

The assays were performed for all isoniazid non-exposed strains (#0) and at passages #1 and #26 of the two exposure processes (A and B).

The EtBr accumulation assays, used to determine the highest concentration of EtBr that cells can handle without detectable accumulation (see Material and Materials), showed that the clinical strains are able to handle higher EtBr concentrations than H37Rv (0.25–0.5 and 0.125 µg/ml of EtBr, respectively – see values at bold type in legends of Figure 3A). This means that the
concentration at which EtBr influx and efflux reach steady state equilibrium is higher for the clinical strains than for H37Rv, i.e.
that the former have higher efflux capacity than that of the reference strain [29]. With exposure to isoniazid, this efflux capacity increase, as shown by the flatness of the accumulation curves observed for all cultures at the first step of isoniazid exposure (Fig. 3B). With continuation of exposure to isoniazid, this efflux activity decreases, as shown by the lower EtBr concentra-
tions needed to reach observable accumulation for cultures at passage #26 (cf. Fig. 3C with 3B), however not to the original levels shown by the non-exposed cultures (cf. Fig. 3C with 3A). Interestingly, this decrease of efflux activity with the prolonged exposure to isoniazid is observable for the clinical strains but not for H37Rv. For the sake of space, only the results for exposure process A are shown in Figure 3, but the same behavior was obtained for the exposure process B, for all the strains.

Figure 1. Schematic representation of exposure of strain H37Rv to 0.1 µg/ml INH using the BACTEC™ MGIT™ 960 and characterization assays performed at selected points. For each strain, exposure to INH was done in duplicate, in two independent assays - processes A and B. INH(a): exposure process A; INH(b): exposure process B; INH: isoniazid; EI: efflux inhibitor. Vertical arrows represent transfer to new MGIT tubes containing 0.1 µg/ml INH. Seq: nucleotide sequence determination for specific fragments of the genes involved in the resistance to INH; AST: susceptibility testing to all first line antibiotics. MICINH: minimum inhibitory concentration determination of isoniazid. Note: This same procedure, here depicted as an example, was carried out for isoniazid exposure of each strain involved in this study.

doi:10.1371/journal.pone.0034538.g001
These assays were then performed using the EtBr concentrations for which influx-efflux are at equilibrium, but now in the presence of verapamil (efflux inhibitor) at sub-inhibitory concentrations (see dotted curves in Figure 3). Results clearly show that inhibition of efflux occurs, leading to an increased EtBr accumulation within cells. Again, this effect is more pronounced at the first step of isoniazid exposure (passage #1), except for H37Rv, which reinforces the hypothesis that this is the step in which the increase of efflux activity is more significant. Similar results were obtained for thioridazine and chlorpromazine, however with lower inhibitory effect (data not shown).

Table 1. The effect of serial passages in a constant concentration of isoniazid (0.1 μg/ml) on the INH MIC and the number of days required for detection of growth.

| INH MIC (μg/ml) | (days required for detection of growth) | #0 | #1 | #2 | #3 | #5 | #13 | #26 |
|-----------------|----------------------------------------|----|----|----|----|----|-----|-----|
| **Fully susceptible strains** | | | | | | | | |
| H37Rv INH (a)   | 0.05 (-)                               | 128 (19) | 128 (5) | 128 (4) | 128 (4) | 128 (4) | 128 (4) |
| H37Rv INH (b)   | 0.05 (-)                               | 128 (14) | 128 (8) | 128 (5) | 128 (3) | 128 (3) | 128 (3) |
| 401/06 INH (a)  | 0.1 (-)                                | 256 (20) | 256 (6) | 256 (4) | 256 (4) | 256 (4) | 256 (3) |
| 401/06 INH (b)  | 0.1 (-)                                | 64 (32)  | 256 (14) | 256 (18) | 256 (7) | 256 (4) | 256 (3) |
| **Rifampicin monoresistant strains** | | | | | | | | |
| 267/05 INH (a)  | 0.1 (-)                                | 128 (15) | 128 (7) | 128 (4) | 128 (6) | 128 (3) | 128 (3) |
| 267/05 INH (b)  | 0.1 (-)                                | 128 (17) | 128 (5) | 128 (4) | 128 (7) | 128 (4) | 128 (3) |
| 359/03 INH (a)  | 0.05 (-)                               | 256 (18) | 256 (13) | 256 (6) | 256 (4) | 256 (4) | 256 (3) |
| 359/03 INH (b)  | 0.05 (-)                               | 128 (17) | 256 (16) | 256 (3) | 256 (3) | 256 (8) | 256 (3) |

Legend: INH: isoniazid; RIF: rifampicin; INH (a)/(b): adaptation processes to isoniazid A and B, respectively.

doi:10.1371/journal.pone.0034538.t001

Table 2. Genotypic characterization of the strains and derived cultures exposed to isoniazid (adaptation process A).

| Strain/Passage | Genotype MTBDRplus | DNA Sequencing | MIRU-VNTR profile |
|----------------|--------------------|----------------|-------------------|
|                | rpoB   mabA-inhA katG | mabA-inhA katG |                   |
| H37Rv          | Wt      wt       wt   | wt             wt   | H37Rv             |
| H37Rv INH (a)  | Wt      wt       wt   | wt             wt   | H37Rv             |
| H37Rv INH (a)2 | Wt      wt       wt   | wt             wt   | H37Rv             |
| H37Rv INH (a)3 | Wt      wt       Δ katG | wt             Δ katG |                   |
| H37Rv INH (a)5 | Wt      wt       Δ katG | wt             Δ katG | H37Rv             |
| H37Rv INH (a)13| Wt      wt       Δ katG | wt             Δ katG |                   |
| H37Rv INH (a)26| Wt      wt       Δ katG | wt             Δ katG | H37Rv             |
| 401/06         | Wt      wt       wt   | wt             wt   | A                 |
| 401/06 INH (a)  | Wt      wt       wt   | wt             wt   | A                 |
| 401/06 INH (a)13| Wt      wt       wt   | wt             wt   | A                 |
| 267/0S         | S531L   wt       wt   | wt             wt   | B                 |
| 267/05 INH (a)  | S531L   wt       wt   | wt             wt   | B                 |
| 267/05 INH (a)13| S531L   wt       wt   | wt             wt   | B                 |
| 267/05 INH (a)26| S531L   wt       wt   | wt             wt   | B                 |
| 359/03         | S531L   wt       wt   | wt             wt   | C                 |
| 359/03 INH (a)  | S531L   wt       wt   | wt             wt   | C                 |
| 359/03 INH (a)2 | S531L   wt       wt   | wt             wt   | Δ katG→STOP      |
| 359/03 INH (a)13| S531L   wt       wt   | wt             wt   | Δ katG→STOP      |
| 359/03 INH (a)26| S531L   wt       wt   | wt             wt   | Δ katG→STOP      |

Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; Δ: deletion of katG gene; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,2,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2; profile B: 2,4,2,2,2,3,3,2,3,2,3,2,2,2,2,2,2,2,2,2,2,2,2,2; profile C: 2,1,4,2,1,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2. doi:10.1371/journal.pone.0034538.t002
Finally, we evaluated the expression levels of genes coding for the main *M. tuberculosis* efflux pumps for cultures at the different isoniazid exposure steps.

### Expression analysis of genes coding for efflux pumps in response to isoniazid

The analysis of the relative expression of efflux pump genes previously identified as transporters of isoniazid was performed for all strains at passages #1 and #26. As detailed in Material and Methods, the expression levels of these genes were determined in the presence of isoniazid and compared to those obtained for the non-exposed culture (#0) [30].

Table 5 shows that the four strains reacted to the presence of isoniazid by overexpressing the majority of the efflux pump genes tested in a way that is not consistent among the two isoniazid exposures processes to which each strain was submitted. Additionally, and perhaps the most striking observation resulting from expression data, was the absence of a clearly defined pattern of gene expression in response to isoniazid exposure. Nevertheless, a general and strong increase in the expression was observed for the majority of the genes tested, *mmpL7*, *p55*, *efpA*, *mmr*, Rv1258c and Rv2459.

### Discussion

In this work, we addressed three questions related to the molecular mechanisms involved in *M. tuberculosis* resistance to isoniazid: i. What are the effects of continuous exposure of *M. tuberculosis* strains to the critical concentration of isoniazid? ii. What are the biological events involved, in particular, which is the role played by efflux pumps in the emergence of resistance? and, iii. Does the final outcome vary when independent exposures are performed for the same strain?

For this purpose, we studied a panel of four *M. tuberculosis* strains, two fully susceptible and two monoresistant to rifampicin, through their independent exposure to a constant concentration of 0.1 mg/ml of isoniazid. During this process, strains became phenotypically resistant with an increase in their INH MIC exceeding 64 mg/ml, which is considered high-level resistance.

The susceptibility towards the other 1st line anti-tuberculosis drugs was not affected by this process, indicating the development of an isoniazid specific resistance mechanism.

In terms of the biological events occurring during exposure to isoniazid (question ii), we observed that for two strains, alterations occurred at the *katG* gene, corresponding to a full deletion in the case of H37Rv and the introduction of a stop codon for strain 359/03. Both alteration occurred early in the exposure process.
and were maintained for the remaining of the assays. These alterations in katG correlated with the loss of catalase activity (data not shown). The mutation found in clinical isolate 359/03 is rarely described in literature; however it fits into the known strategy of KatG functional weakening by introduction of mutations during isoniazid exposure [10,31]. Others have also reported the in vitro deletion of total or part of the katG gene in strains exposed to isoniazid [31,32], and total/partial deletion of the katG gene of isoniazid-resistant clinical isolates has also been previously reported [8,33]. Interestingly, no genetic changes were detected in the second isoniazid-exposure procedure, run in parallel for these same strains, indicating that evolution of the same strain in the same conditions can bring about, in a non-deterministic course, cells that significantly differ both phenotypically and genetically.

Our results clearly show that, in addition to the occurrence of spontaneous mutations, efflux systems play a role in the development of isoniazid resistance. This occurs quite early during exposure to isoniazid and allows cells to survive in the presence of this antibiotic until a mutation conferring high level and stable resistance emerges. Recently, Srivastava et al., suggested a model for the development of drug resistance in the M. tuberculosis reference strain H37Rv, enabling the rapid emergence of high level resistance to both ethambutol and isoniazid [34]. In this model, it is proposed that induction of an efflux pump which transports two or more drugs is the first step to the emergence of resistance. Our results provide the experimental data that confirm the model proposed by these authors and demonstrate that this mechanism is extendable to clinical isolates.

Moreover, our work provides, for the first time, data captured on a real-time basis for increased efflux activity as the first-line response of M. tuberculosis to the critical concentration of isoniazid. This efflux-mediated response was detected for both susceptible and rifampicin monoresistant, reference or clinical strains and provide the cells with a rapid, non specific response to a highly noxious agent. As the isoniazid exposure process continues, two different patterns were observed: the susceptible reference strain H37Rv increased its efflux activity, even after deletion of the entire katG gene, whereas the clinical strains showed a decreased efflux activity in the last passage of isoniazid exposure. During the entire process, the clinical strains showed a capacity to handle higher EtBr concentrations than H37Rv, an additional evidence of their higher efflux capacity. Overall, the clinical strains appear to be more prompt to respond, via an efflux-mediated pathway, to noxious agents, such as EtBr or isoniazid, whereas H37Rv shows a less prompt, but more stable/prolonged use of efflux as a detoxifying response to these drugs. These results suggest that clinical M. tuberculosis strains are primed to efflux noxious compounds, as already observed in other bacteria [35]. The presence of such efflux system(s) and their role in resistance to these drugs was additionally confirmed by the use of efflux inhibitors in both real-time efflux assays and MIC determinations. While in the first assays, these compounds were able to reduce efflux of EtBr, their use in INH MIC determination showed the involvement of efflux on the high level resistance to this antibiotic. For some strains, the reduction on INH MIC by the EIs tested reached levels identical to their susceptible parental counterparts. This clearly shows that in these cases, high level isoniazid resistance is mainly efflux-driven. From the several inhibitors tested, chlorpromazine and verapamil were the two most effective for inhibiting isoniazid efflux in M. tuberculosis, as previously demonstrated for M. tuberculosis complex [36].

It is worth noticing that EIs show a more significant effect on the MICs for cultures at first passage compared to their effect on the MICs of the last passage (#26). For strain 401/06, submitted to exposure process A, despite the fact that no evident genetic alteration was detected, the high INH MIC obtained after isoniazid exposure could not be reduced by any of the EIs tested (Table 4). This result suggests that, for this culture, the isoniazid high level resistance detectable at first passage is already mutation-driven. Interestingly strain 267/05, without detectable mutations is the one with the highest level of expression of genes for efflux further supporting that overexpression of efflux-pumps can sustain isoniazid resistance to levels as high as those achieved by the canonical mutations.

To identify the efflux system(s) involved in this first-line response to isoniazid, we selected a set of genes coding for efflux pumps reported to be involved in the transport of noxious substances,
Figure 3. Accumulation of EtBr by the *M. tuberculosis* strains tested. The figure shows the accumulation of EtBr by the strains from adaptation process A as an example. The values at bold type correspond to the higher concentration of EtBr that cells can handle without detectable accumulation. The dotted line corresponds to the assay run using the EtBr concentrations for which influx-efflux are at equilibrium, in the presence of the Ei verapamil, at sub-inhibitory concentrations. Panel (A): Parental strains (passage #0); Panel (B) strains after first passage with INH and Panel (C); strains after 26 passages with INH. INH: isoniazid.

doi:10.1371/journal.pone.0034538.g003
including isoniazid [12,15,37]. The detection by RT-qPCR of highly increased expression of these genes following isoniazid exposure, further evidences that an efflux-mediated response provides an early stress response that creates opportunity for other resistance mechanisms to arise.

Although we detected a general and marked increase of efflux pumps genes, most of which being significantly overexpressed, we also noted the absence of a clearly defined pattern of specific gene expression in response to isoniazid exposure. Efflux pumps seem to be promiscuous in their activity as we cannot associate extrusion of isoniazid to a specific gene. Similar results were obtained by others which was always well above 64 \( \mu \)g/ml of isoniazid. Nevertheless, they all respond in a similar way at the first steps of this process and that is through isoniazid efflux, which may constitute an early stress response of bacteria against environmental noxious agents such as appears to be the case for isoniazid. After this first, efflux-mediated response, evolution may take different non-deterministic paths conducting to high level resistance. Collectively, these observations support the experimental strategy followed in this work that highlighted alternative pathways by which the same \( M. tuberculosis \) strain responds to 0.1 \( \mu \)g/ml isoniazid, all resulting in the same high resistance level.

In conclusion, constant exposure of \( M. tuberculosis \) to the commonly used critical concentration of isoniazid causes susceptible strains to become highly resistant to this key anti-tuberculosis drug. The same procedure applied to strains initially mono-resistant to rifampin results in the development of multidrug resistance as defined by the WHO, i.e., resistance to isoniazid and rifampin. To our knowledge, this is the first presentation of an in vitro process that mimics the development of multidrug resistant  \( M. \)

| Table 5. Average quantification of the relative expression level, by RT-qPCR, of the genes that code for efflux pumps in \( M. tuberculosis \) in the two independent isoniazid exposure processes. |
|---------------------------------|---|
| **Relative expression level ± SD** | |
| \( mmpL7 \) & \( Rv1258c \) & \( p55 \) & \( efpA \) & \( mnr \) & \( Rv2459 \) |
| **Fully susceptible strains** | |
| H37Rv INH(a)1 & 8.00 ± 2.38 & 16.00 ± 1.16 & 13.00 ± 2.23 & 9.85 ± 1.41 & 16.65 ± 2.44 & 25.99 ± 2.56 |
| H37Rv INH(a)26 & 0.44 ± 0.12 & 1.99 ± 0.66 & 0.82 ± 0.15 & 0.34 ± 0.28 & 0.44 ± 0.16 & 0.50 ± 0.02 |
| H37Rv INH(b)1 & 10.56 ± 3.48 & 15.26 ± 0.46 & 6.96 ± 1.36 & 8.00 ± 2.98 & 9.95 ± 2.03 & 22.63 ± 1.56 |
| H37Rv INH(b)26 & 4.57 ± 0.25 & 2.53 ± 0.03 & 2.70 ± 0.43 & 4.41 ± 0.21 & 1.54 ± 0.29 & 2.31 ± 0.13 |
| 401/06 INH(a)1 & 34.30 ± 1.24 & 22.63 ± 0.47 & 18.38 ± 1.94 & 16.00 ± 1.32 & 24.25 ± 2.34 & 9.19 ± 0.11 |
| 401/06 INH(a)26 & 17.15 ± 0.23 & 14.93 ± 2.30 & 9.85 ± 0.99 & 6.96 ± 1.57 & 9.19 ± 1.76 & 27.86 ± 1.3 |
| 401/06 INH(b)1 & 1.53 ± 0.29 & 1.77 ± 0.75 & 3.47 ± 1.16 & 6.50 ± 1.30 & 1.47 ± 0.07 & 0.20 ± 0.05 |
| 401/06 INH(b)26 & 4.16 ± 0.66 & 7.80 ± 4.96 & 11.31 ± 1.11 & 8.57 ± 2.66 & 2.29 ± 0.77 & 2.64 ± 0.39 |
| **Rifampicin monoresistant strains** | |
| 267/05 INH(a)1 & 6.06 ± 0.53 & 4.29 ± 0.24 & 5.28 ± 0.48 & 9.85 ± 0.17 & 3.73 ± 0.13 & 6.50 ± 1.03 |
| 267/05 INH(a)26 & 115.56 ± 59.44 & 53.85 ± 2.64 & 110.80 ± 66.17 & 341.05 ± 66.43 & 59.06 ± 53.66 & 32.00 ± 1.98 |
| 267/05 INH(b)1 & 5.01 ± 1.10 & 2.00 ± 0.21 & 3.10 ± 0.43 & 3.90 ± 0.28 & 2.62 ± 0.54 & 1.69 ± 0.36 |
| 267/05 INH(b)26 & 17.15 ± 1.24 & 3.04 ± 0.29 & 12.13 ± 0.67 & 22.63 ± 3.09 & 3.89 ± 0.57 & 0.64 ± 0.09 |
| 359/03 INH(a)1 & 4.00 ± 0.03 & 1.62 ± 0.54 & 2.08 ± 1.06 & 1.87 ± 0.00 & 2.03 ± 0.86 & 0.76 ± 0.09 |
| 359/03 INH(a)26 & 13.96 ± 1.36 & 9.01 ± 2.17 & 8.53 ± 2.86 & 10.66 ± 2.07 & 11.46 ± 4.9 & 32.00 ± 2.01 |
| 359/03 INH(b)1 & 9.85 ± 2.35 & 5.66 ± 1.24 & 4.00 ± 0.06 & 5.11 ± 2.62 & 6.06 ± 0.54 & 0.25 ± 0.03 |
| 359/03 INH(b)26 & 25.99 ± 1.33 & 29.86 ± 3.29 & 29.86 ± 2.56 & 2.30 ± 0.83 & 10.56 ± 1.36 & 2.30 ± 0.12 |

Legend: (a): exposition process A, first passage; (b): exposition process B, first passage; (a)26: exposition process A, passage twenty six; (b)26: exposition process B, passage twenty six. The relative expression of the efflux pump genes was assessed by comparison of the relative quantity of the respective mRNA in the presence of isoniazid to the non-exposed strain. Each culture was assayed in triplicate using total RNA obtained from three independent cultures. A level of relative expression equal to 1 indicates that the expression level was identical to the strain that was being compared. Genes showing expression levels equal or above four, when compared to the non-exposed strain, were considered to be overexpressed and are shown in bold.

doi: 10.1371/journal.pone.0034538.t005
*tuberculosis* strains, which correlates with the anticipated development of MDR-TB in a patient treated for prolonged periods with a constant dose of isoniazid, as needed for effective therapy. Therefore, the results obtained in this work emphasize the need for revising isoniazid critical concentration and reinforce the importance of multiple drug therapy in all anti-tuberculosis regimens [45,46]. Furthermore, efflux inhibitors like the ones tested in this work represent relevant alternatives in the search for new effective compounds and new therapeutic strategies for preventing the emergence of and possibly in the treatment of MDR-TB.

**Materials and Methods**

*M. tuberculosis* strains

The strains studied included two *M. tuberculosis* strains susceptible to the first-line antibiotics, the reference strain H37Rv ATCC27294 and a clinical isolate 401/06, plus two clinical isolates 359/03 and 267/05, both monoresistant to rifampicin, harboring the most common *rpoB* mutation in clinical isolates, S531L, all from the culture collection of Grupo de Mico bacterias, Unidade de Microbiologia Medica, Instituto de Higiene e Medicina Tropical (IHMT, UNL).

Cultures, susceptibility testing, minimum inhibitory concentration (MIC) determination and antibiotic exposure process was conducted using the BACTEC™ MGIT™ 960 system (BACTEC 960) and the Epicenter V5.53A software equipped with the TB eXIST module (Becton Dickinson Diagnostic Systems, Sparks, MD, USA).

Antimicrobial agents

The lyophilized drugs (BACTEC™ MGIT™ 960 SIRE and PZA kits; SIRE: streptomycin, isoniazid, rifampicin and ethambutol; PZA: pyrazinamide) used in the standard susceptibility testing and in the exposure process to isoniazid and rifampicin were purchased from Becton Dickinson and the stock solutions prepared as per the manufacturer’s instructions. Isoniazid for MIC determination and efflux inhibitors verapamil, thioridazine and chlorpromazine, as well as the efflux substrate ethidium bromide (EtBr), were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs were prepared in sterile deionized water.

Exposure process to the critical concentration of isoniazid

Each strain was exposed to isoniazid (0.1 μg/ml) in duplicate (Figure 1 – Schematic example for isoniazid exposure of strain H37Rv ATCC27294). This concentration is defined as the lowest concentration necessary to inhibit 99% of the wild-type strains of *M. tuberculosis* that were never in contact with this antibiotic, and is the critical concentration used for the BACTEC™ MGIT™ 960 SIRE AST procedure [47,48]. Briefly, the exposure process for strains susceptible to isoniazid began with the preparation of MGIT tubes containing SIRE supplement (Becton Dickinson) and 0.1 μg/ml of isoniazid. These tubes were then inoculated with 0.5 ml of the initial culture and subsequently incubated at 37°C in the BACTEC 960 system until full growth was evident. For each strain, this process was done in duplicate – see Figure 1 for example.

For convenience, the various passages of the strains are identified as follows: strain number, antibiotic, exposure process (A or B) and the number of the passage. For example, H37RvINH(A26) refers to strain H37Rv exposed to isoniazid, exposure process A, passage 26 – see Figure 1 for example.

MIC determination and antibiotic susceptibility testing

(i) **MIC determination.** The MICs of the antibiotics and efflux inhibitors (EIs) were performed in accordance to the procedures issued by the manufacturer of the BACTEC 960 system revised by Springer et al. [48,49] for the parental strains at the initial process and periodically for each of the progeny cultures (Figure 1). The concentrations used were as follows: isoniazid: 0.025 to 256 μg/ml; verapamil: 30 to 512 μg/ml; thioridazine and chlorpromazine: 7.5 to 60 μg/ml; EtBr: 0.25 to 4 μg/ml. At the time of testing, two-fold serial dilutions were prepared to achieve the desired concentrations. Each drug-containing tube was inoculated with 0.8 ml of SIRE supplement, 0.1 ml of each drug in the appropriated concentration and 0.5 ml of the culture. For the preparation of the drug-free growth control tube (proportional control), the culture was diluted 1:100 with a sterile saline solution and 0.5 ml transferred into a new MGIT tube. Additionally, a second drug-free growth control, inoculated with 0.5 ml of the undiluted suspension of the strain, was prepared and served as absolute control for inoculums errors. The tubes were inserted in the BACTEC 960 system and growth monitored with the TB eXIST module. The interpretation of the results was performed as proposed by Springer et al. [49].

(ii) **Isoniazid MIC determination in the presence of EIs.** The MICs of isoniazid (INH MIC) in combination with the EIs were performed in the first passage where the increased resistance was first noticed and in the last passage (#26) of the serial exposure process to isoniazid – Figure 1. The EIs were used at a concentration corresponding to ½ of the respective MIC. This concentration was selected since it has no effect on the growth of the strains following the protocol described above.

(iii) **Susceptibility testing in the presence and absence of EIs.** For standard susceptibility testing against isoniazid, rifampicin, pyrazinamide, streptomycin and ethambutol, the readings were automatically interpreted by the BACTEC 960 system and reported as either susceptible or resistant. The preparation of the drug containing tubes and controls was done as described above. For the susceptibility testing for isoniazid in the presence of the EIs, the tubes containing 0.1 μg/ml of isoniazid were inoculated with the EI at ½ of the MIC.

Genotypic characterization of the strains

(i) **DNA extraction.** Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN, GmbH, Hilden, Germany) according to the manufacturer’s instructions.

(ii) **Screening of mutations.** The most common mutations in *rpoB*, katG and the *mabA-inhA* operon were screened during the exposure process, using the system Genotype MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) according to the manufacturer’s instructions.

(iii) **DNA sequencing.** The analysis of internal fragments of the genes associated with isoniazid resistance, katG and the *mabA-inhA* operon, was performed according to Perdigão et al. [50].

(iv) **MIRU-VNTR analysis.** MIRU-VNTR genotyping was performed for each strain and at defined passages of the exposure process by multiplex PCR amplification of 24 MIRU–VNTR loci, as described by Supply et al. [51].

Quantification of expression of genes coding for efflux pumps by RT-qPCR

(i) **RNA extraction.** Total RNA was isolated from the cells using the RNeasy mini kit (QIAGEN) according to the manufacturer’s instructions. Briefly, from a culture with 100–200 GU (about 10⁶–10⁷ cells/ml), 1 ml aliquot was removed and centrifuged at 13 000 rpm during 10 minutes. Then, 500 μl

---

*Plasmodium falciparum* and *Toxoplasma gondii*.
Table 6. Sequences of the primers used in the RT-qPCR assays.

| Gene     | Primer Sequence (5‘-3’) | Amplification product (bp) | Reference |
|----------|-------------------------|---------------------------|-----------|
| mmpL7_Fw | TAC CCA AGC TGG AAA CAA | 214                       | [36]      |
| mmpL7_Rv | CCG TCA GAA TAG AGG AAC CAG | 214                      | [36]      |
| p53_Fw   | AGT GGG AAA TAA GCC AGT AA | 198                     | [36]      |
| p53_Rv   | TGG TTG ATG TCG AGC TGT | 198                       | [36]      |
| efpA_Fw  | ATG GTA ATG CCT GAC ATC C | 131                      | [36]      |
| efpA_Rv  | CTA CGG GAA ACC AAC AAA G | 131                      | [36]      |
| mnr_Fw   | AAC CAG CCT GCT CAA AAG | 221                       | [36]      |
| mnr_Rv   | CAA CCA CCT TCA TCA CAG A | 221                     | [36]      |
| Rv1258c_Fw | AGT TAT AGA TCG GCT GGA TG | 268                   | [36]      |
| Rv1258c_Rv | GTC CTG TTC CCG AAA TAC | 268                      | [36]      |
| Rv2459_Fw | CAT CTT CAT GGT GTT GCT G | 232                 | This study|
| Rv2459_Rv | CGG TAG CAC ACA GAC AAT AG | 232                 | This study|
| 16S_Fw   | CAA GGC TAA AAC TCA AAG GA | 197                    | [36]      |
| 16S_Rv   | GGA CTT AAC CCA ACA TCT CA | 197                    | [36]      |

FW: forward; RV: reverse.

doi:10.1371/journal.pone.0034538.t006

supernatant was removed and 1 ml of RNAprotect Bacteria reagent (QIAGEN) added. An enzymatic lysis step was carried out with lysozyme at 3 μg/ml (Sigma) for 10 minutes, followed by lysis in an ultrasonic bath at 35 kHz (Gen-Probe, California, USA) during 15 minutes. The RNA was then purified using the RNeasy kit (QIAGEN) and treated with RNase-free DNase I (QIAGEN) during 2 hours and 15 minutes by on-column digestion at room temperature to reduce the presence of contaminating DNA. All RNA samples were aliquoted and frozen at -20°C until required.

(ii) RT-qPCR assay. The relative expression level of the genes that code for the main membrane efflux transporters in M. tuberculosis (mmpL7, p53, efpA, mnr, Rv1258c and Rv2459) were analyzed by RT-qPCR in the first passage where the increased resistance was first noticed and in last passage (#26) of the exposure process to isoniazid – Figure 1. The normalization of the data was done using the M. tuberculosis 16S rDNA for each experiment. The forward and reversed primers employed are described in Table 6. The RT-qPCR procedure was performed in a Rotor-Gene™ 3000 thermocycler and followed the protocol recommended for use with the Quantitect SYBR Green RT-PCR Kit (QIAGEN). The determination of the relative mRNA expression level was performed using the comparative quantification cycle (Cq) method [40]. The relative expression of the six efflux pump genes analyzed by comparison of the relative quantity of the respective mRNA in the presence of isoniazid to the non-exposed culture, following the same technical approach previously published [30]. Each culture was assayed in triplicate using total RNA obtained from three independent cultures. A level of relative expression equal to 1 indicates that the expression level was identical to the unexposed strain. Genes showing expression levels equal or above four, when compared with the unexposed strain, were considered to be overexpressed [29,52]. The assays were performed based on the protocol previously described [28,29,52] with modifications due to the growth features of this microorganism, mainly the slow generation time and the minimization of cell clumps. Increased biosafety measures were taken to prevent the production and dispersal of aerosols with infective particles since we were dealing with a Level 3 pathogen. The semi-automated fluorometric method was applied to the initial strains and to the isoniazid exposed strains, at the first passage where the increased resistance was first noticed and in the last passage (#26) of the adaptation process to isoniazid independently of the genetic background of each adapted culture.

The strains were grown in 100 ml of Middlebrook 7H9 medium (DIFCO, Madrid, Spain) in Erlenmeyer flasks containing 10% OADC enrichment (Becton Dickinson) and 0.05% Tween 80. All cultures were incubated at 37°C, without stirring, until they reached an approximate optical density at 600 nm (OD600) of 0.8 (mid-log phase). After the cultures reached the desired OD600, 25 ml cultures were centrifuged at 2700 g during 3 minutes at 25°C. After this, the supernatant were discarded, the pellet washed, resuspended in PBS and centrifuged as before. This procedure was performed twice. For accumulation assays, the washed cells were re-suspended in PBS and the OD600 adjusted to 0.8. In order to determine the lowest concentration of EtBr that causes accumulation, 50 μl of the bacterial suspension was added to 0.2 ml PCR tubes containing different concentrations of EtBr that ranged from 0.0625 to 5 μg/ml and glucose at a final concentration of 0.4%. The final OD600 of the bacterial suspension in the assay was 0.4. The assays were conducted at 37°C in a Rotor-Gene 3000™, and the fluorescence of EtBr was measured (530/585 nm) at the end of each cycle of 60 seconds, for 60 minutes. After determining the higher concentration of EtBr that do not causes accumulation, the effect of the EIs verapamil, thioridazine and chlorpromazine on the accumulation of EtBr was evaluated. These assays were performed like described above with each EI at 1/2 of the MIC, EtBr at the higher concentration that do not cause accumulation (determined for each strain and adapted cultures), 37°C and with glucose.

Semi-automated fluorometric method

This method allows the real-time fluorometric detection of the accumulation and extrusion of EtBr, using the Rotor-Gene 3000™ thermocycler (Corbett Research, Sydney, Australia) [29,52].
The authors are grateful to Becton Dickinson (USA) and Quilabain (Portugal) for having provided the TB-eXIST module.

References

1. World Health Organization (2011) Global tuberculosis control. WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: World Health Organization.

2. Somoskovi A, Parsons LM, Salfighters M (2001) The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2: 164–168.

3. Telenti A, Imboden P, Marchesi F, Lorriger D, Cole S, et al. (1995) Detection of rifampin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 414–415.

4. Vieviore M, Leandro C, Rodrigues L, Almeida J, Bettencourt R, et al. (2005) Direct application of the INNO-LIPA Rif/TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 43: 4830–4834.

5. World Health Organization (2008) Anti-tuberculosis drug resistance in the world. Fourth Global Report. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2002–2007. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization.

6. Zhung Y, Heym B, Allen B, Young D, Cole S (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591–593.

7. Barone J, Dubhna E, Kruma H, Balasubramanian U, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethambutol in Mycobacterium tuberculosis. Science 263: 227–230.

8. Heym B, Alzari PM, Honore N, Cole ST (1995) Misense mutations in the catalase-peroxidase gene, katE, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Biol 15: 235–245.

9. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y, et al. (2006) Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 55: 1527–1531.

10. Vichere C, Jacobs VR, Jr. (2007) The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 61: 35–50.

11. Hazboun MH, Brmacome M, del Valle MB, Cavatone M, Guerrero MI, et al. (2008) Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 52: 2640–2649.

12. Louw GE, Warren RM, van Puttis NC, McEvoy CR, van Helden PD, et al. (2009) A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53: 3101–3109.

13. Vieviore M, Leandro C, Amaral L (2003) Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents 22: 274–278.

14. Cole ST, Bosh C, Parkhill J, Garther F, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537–544.

15. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, et al. (2010) Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculosis drugs. Microb Drug Resist 16: 21–28.

16. Rodrigues L, Ainsa JA, Amaral L, Viveiros M (2011) Contribution of efflux drug pumps in macrolide resistance in Mycobacterium avium complex. J Antimicrob Agents 45: 279–283.

17. Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, et al. (2009) The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. J Antimicrob Agents 43: 529–533.

18. Paixao L, Rodrigues L, Couto I, Martins M, Fernandes P, et al. (2009) Phlorotannin determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng 3: 18.

19. Vieviore M, Dupont M, Rodrigues L, Couto I, Davin-Rega A, et al. (2007) Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE 2: 963.

20. de Serevnikel M, de Kruet GJ, Kate MF, van Belkum A, Verbrugh HA, et al. (2010) Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 65: 2502–2508.

21. Bergcld II, Schuitma ARJ, Klaster PR, Anthony RM (2009) Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 64: 515–523.

22. Vidalie B, Negeer S, Noursoukva A, Andersen AB, Thomsen VO, et al. (2008) Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 27: 1079–1086.

23. Sivartasta S, Musauk S, Sherman C, Merck C, Leff R, et al. (2010) Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 201: 1225–1231.

24. Costa SS, Faleco C, Vieviore M, Machado D, Martins M, et al. (2011) Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 11: 241.

25. Rodrigues L, Machado D, Couto I, Amaral L, Vieviore M (2011) Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol. doi:10.1016/j.ijge.2011.08.009.

26. da Silva PEA, Grooss AV, Martin A, Palomino JC (2011) Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEBS Immunol Med Microbiol 52: 1–9.

27. Louw GE, Warren RM, van Puttis NC, Leon R, Jinmez A, et al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobac- terium tuberculosis through efflux. Am J Respir Crit Care Med 180: 289–296.

28. De Marco GE, Cushing LA, Longmon-Mano L, Ero-Mem, J, Baraiza TA, et al. (2007) Efflux-related resistance to norfloxacin, dyes and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 51: 3235–3239.

29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25: 402–408.

30. Portevin D, de Sousa-D’Auria C, Housin C, Grimaldi C, Baill MCM, et al. (2004) A polychrome synthese catalyse the last condensation step of mycic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci USA 101: 314–319.

31. Cox JS, Chen B, McNeil M, Jacobs WR, Jr. (1999) Complex lipid determines tissue replication of Mycobacterium tuberculosis in mice. Nature 250: 2503–2511.

32. Blanco MV, Blanco FC, Imperiale B, Ferrellad MA, Rocha RV, et al. (2011) Role of P22 P55 operon from Mycobacterium tuberculosis in the resistance to toxic compounds. BMC Infect Dis 11: 195.

33. Wilson M, DeRisi J, Krutsisn H-H, Imboden P, Rane S, et al. (1999) Exploring drug induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96: 12833–12837.

34. Botter E (2011) The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17: 1128–1134.

35. Zunla A, Aan R, Maurer M, Mscala P, Ma Z, et al. (2011) Viewpoint: Scientific dogmas, paradoxes, and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 16: 79–83.

36. Inderlied CB, Nash KA (1996) Antimycobacterial agents: in vitro susceptibility testing, spectra of action, mechanisms of action and resistance, and assays for activity in biologic fluids. J Toxicol Virology in laboratory medicine, 3rd ed. Williams and Wilkins, Baltimore, USA pp 127–175.

37. Siddiqui S, Rusch-Gerdes S (2006) MGIT960 Procedure Manual for BACTEC 460 TGM 906 TB System (Also applicable for Manual MGIT).

Author Contributions

Conceived and designed the experiments: DM IC LR MV LA IP BV. Performed the experiments: DM JP LR. Analyzed the data: DM IC MV LA BP BV. Wrote the paper: DM IC LA BP MV.
Mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects. Foundation for innovative new diagnostics Ed.

49. Springer B, Lücke K, Calligaris-Maibach R, Ritter C, Böttger EC (2009) Quantitative drug susceptibility testing of Mycobacterium tuberculosis using MGIT960® and the EpiCenter instrumentation. J Clin Microbiol 47: 1773–1780.

50. Perdigão J, Macedo R, João I, Fernandes E, Brum L, et al. (2008) Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 14: 133–143.

51. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, et al. (2006) Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44: 4498–4510.

52. Viveiros M, Rodrigues I, Martins M, Couto I, Spengler G, et al. (2010) Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol 642: 159–172.